The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction

Disruption of the interaction between the ubiquitination facilitator protein Keap1 and the transcription factor Nrf2 is a potential strategy for enhancing the expression of antioxidant and detoxification gene products that are regulated by this cap ‘n’ collar basic-region leucine zipper transcriptio...

Full description

Bibliographic Details
Main Author: Hancock, R. M.
Published: University College London (University of London) 2013
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626046
id ndltd-bl.uk-oai-ethos.bl.uk-626046
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-6260462015-12-03T03:29:38ZThe discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interactionHancock, R. M.2013Disruption of the interaction between the ubiquitination facilitator protein Keap1 and the transcription factor Nrf2 is a potential strategy for enhancing the expression of antioxidant and detoxification gene products that are regulated by this cap ‘n’ collar basic-region leucine zipper transcription factor. Agents that disrupt this protein-protein interaction may be useful pharmacological probes and future cancer chemopreventive agents. The activity of Nrf2 is thought to be regulated by at least two other proteins; the nuclear protein prothymosin α and the proteasome associated sequestosome-1 that compete for the Keap1 binding site. The aim of this project is to develop compounds that directly inhibit the Keap1-Nrf2 protein-protein interaction and thereby enhance Nrf2 activity by a mechanism different to that of existing chemopreventive agents. Linear and cyclic peptides based on the binding motifs of Nrf2, prothymosin α and sequestosome-1 were designed and synthesised. An optimised series of peptides was then developed with further changes to the sequence to improve the binding profile. The peptides were shown to inhibit the Keap1-Nrf2 protein-protein interaction, determined using a fluorescence polarisation assay. A small series of stearoyl capped peptides were also developed for use in cell based assays. The peptides can be ranked in order of affinity and used to determine a structure activity relationship for interaction with the Keap1 protein. Cyclic inhibitors were generally more potent than the linear peptides, however, the most potent peptide was a linear hybrid sequence based upon the Nrf2 and sequestosome-1 binding motifs, and with an IC50 of 115 nmol/L was more active than either native sequence alone and equivalent in activity to the Nrf2 Neh2 domain protein. Finally, a small library of peptidomimetics designed using the peptide template and molecular modelling studies were also synthesised, resulting in five small molecules with IC50 values in the micromolar range.615.1University College London (University of London)http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626046http://discovery.ucl.ac.uk/1386638/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 615.1
spellingShingle 615.1
Hancock, R. M.
The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
description Disruption of the interaction between the ubiquitination facilitator protein Keap1 and the transcription factor Nrf2 is a potential strategy for enhancing the expression of antioxidant and detoxification gene products that are regulated by this cap ‘n’ collar basic-region leucine zipper transcription factor. Agents that disrupt this protein-protein interaction may be useful pharmacological probes and future cancer chemopreventive agents. The activity of Nrf2 is thought to be regulated by at least two other proteins; the nuclear protein prothymosin α and the proteasome associated sequestosome-1 that compete for the Keap1 binding site. The aim of this project is to develop compounds that directly inhibit the Keap1-Nrf2 protein-protein interaction and thereby enhance Nrf2 activity by a mechanism different to that of existing chemopreventive agents. Linear and cyclic peptides based on the binding motifs of Nrf2, prothymosin α and sequestosome-1 were designed and synthesised. An optimised series of peptides was then developed with further changes to the sequence to improve the binding profile. The peptides were shown to inhibit the Keap1-Nrf2 protein-protein interaction, determined using a fluorescence polarisation assay. A small series of stearoyl capped peptides were also developed for use in cell based assays. The peptides can be ranked in order of affinity and used to determine a structure activity relationship for interaction with the Keap1 protein. Cyclic inhibitors were generally more potent than the linear peptides, however, the most potent peptide was a linear hybrid sequence based upon the Nrf2 and sequestosome-1 binding motifs, and with an IC50 of 115 nmol/L was more active than either native sequence alone and equivalent in activity to the Nrf2 Neh2 domain protein. Finally, a small library of peptidomimetics designed using the peptide template and molecular modelling studies were also synthesised, resulting in five small molecules with IC50 values in the micromolar range.
author Hancock, R. M.
author_facet Hancock, R. M.
author_sort Hancock, R. M.
title The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
title_short The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
title_full The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
title_fullStr The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
title_full_unstemmed The discovery and evaluation of inhibitors of the KEAP1-NRF2 protein-protein interaction
title_sort discovery and evaluation of inhibitors of the keap1-nrf2 protein-protein interaction
publisher University College London (University of London)
publishDate 2013
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626046
work_keys_str_mv AT hancockrm thediscoveryandevaluationofinhibitorsofthekeap1nrf2proteinproteininteraction
AT hancockrm discoveryandevaluationofinhibitorsofthekeap1nrf2proteinproteininteraction
_version_ 1718141799084589056